| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/18/2009 | CN101385699A Sustained-released injection containing nitrosourea medicine |
| 03/18/2009 | CN101385697A Flurbiprofen axetil eye nano-emulsion in-situ gel preparation and preparation method thereof |
| 03/18/2009 | CN101385696A Sodium alginate microspheres blood vessel suppository containing etoposide and preparation method and uses thereof |
| 03/18/2009 | CN101385688A Oilwater emulsion composition containing ascorbic acid-2-phosphate ester magnesium salt |
| 03/18/2009 | CN100469792C Regulation of lipid levels via the Zmaxl or HBM gene |
| 03/18/2009 | CN100469789C Variants of allergenic proteins of the Group2 of dermatophagoides |
| 03/18/2009 | CN100469784C Use of glycosides of mono- and diacylglycerol as anti-inflammatory agents |
| 03/18/2009 | CN100469783C Oligose ,sulfating product and oligose cluster and its uses |
| 03/18/2009 | CN100469780C Cysteine protease inhibitors |
| 03/18/2009 | CN100469778C Novel fused imidazole derivative |
| 03/18/2009 | CN100469776C Amelioration of the development of cataracts and other ophthalmic diseases |
| 03/18/2009 | CN100469773C Preparation method and usage for nitrogen-containing flavone derivatives |
| 03/18/2009 | CN100469770C 5-substituted-pyrazine or -pyridine glucokinase activators |
| 03/18/2009 | CN100469769C Benzyl-pyridazinons as reverse transcriptase inhibitors |
| 03/18/2009 | CN100469767C Bipiperidinyl-derivatives and their use as chemokine receptor inhibitors |
| 03/18/2009 | CN100469765C Prostaglandin nitrooxyderivatives |
| 03/18/2009 | CN100469764C Vitamin D derivatives |
| 03/18/2009 | CN100469761C Cycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals |
| 03/18/2009 | CN100469759C Toremifene crystallization method |
| 03/18/2009 | CN100469399C Electrothermal cap for dredging cerebral meridian and its making process |
| 03/18/2009 | CN100469381C Compound capsule for decreasing alcohol and protecting liver |
| 03/18/2009 | CN100469373C Medicine for treating piles and its preparing process |
| 03/18/2009 | CN100469372C Xindakang drip pill and preparation thereof |
| 03/18/2009 | CN100469371C Manufacturing technique for gingko leaf extracts |
| 03/18/2009 | CN100469370C Application of stable HIFalpha preparation in preparing medicament for adjusting fat metabolism |
| 03/18/2009 | CN100469369C Usage of stigmastane-3,5,6-triol and derivative for preparing antiviral remedy, and new stigmastane-3,5,6-triol derivatives |
| 03/18/2009 | CN100469368C Use of adatanserin for treating neurogenerative disorders |
| 03/18/2009 | CN100469367C Transdermal preparations comprising eperisone, tolperisone or salts thereof |
| 03/18/2009 | CN100469366C Pharmaceutical formulation comprising a proton pump inhibitor and antacids |
| 03/18/2009 | CN100469365C Combination of medication for treating colpitis |
| 03/18/2009 | CN100469364C Antiviral medicine, preparation method and application thereof |
| 03/18/2009 | CN100469363C Therapeutic combinations of fatty acids |
| 03/18/2009 | CN100469362C Composite amino acid freeze dried powder injection and its preparation process |
| 03/18/2009 | CN100469361C Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
| 03/18/2009 | CN100469360C Soft capsule of indapamide |
| 03/18/2009 | CN100469356C Slowly released tablet of compound atenolol, and preparation method |
| 03/18/2009 | CN100469353C Balsalazide sodium enteroclyster and its preparing method |
| 03/18/2009 | CN100469348C Cosmetic/dermatological compositions |
| 03/18/2009 | CA2639640A1 Local vascular delivery of mtor inhibitors in combination with peroxisome proliferators-activated receptor stimulators |
| 03/17/2009 | USRE40667 [R-(R*R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid, its lactone form and salts thereof |
| 03/17/2009 | US7504528 Merocyanine derivatives for cosmetic use |
| 03/17/2009 | US7504522 e.g. 3-(2,4,4'-trichlorobenzhydryloxy)-N-(tert-butyl)azetidine-1-carboxamide; cannabinoid receptor antagonist; antidiabetic agent, antidepressant; eating disorders, obesity, nicotine addiction |
| 03/17/2009 | US7504519 e.g. N-Methoxycarbonyl-4-(4,5-dihydro-5-phenyl-3-trifluoromethyl-pyrazole-1-yl)-benzenesulphonamide; antiinflammatory and analgesic agent |
| 03/17/2009 | US7504517 1 -(Methylsulfonylamino)-3 - [2-(4-methoxyphenyl)ethyl]-4-(4-methoxyphenyl) -2-imidazolidinone; atrial-selective antiarrhythmic agents; cardiovascular disorders; arrhytmia, atrial fibrillation, atrial flutter, thromboembolism, stroke, and heart failure |
| 03/17/2009 | US7504513 e.g. 2-(5,6-Dimethoxy-benzoimidazol-1-yl)-4-phenyl-thiazole-5-carboxylic acid; Polo-like kinase 1 inhibitor; antiproliferative, anticarcinogenic, antitumor agent; solid tumors of various origins (breast, lung, colon, stomach, ovary, smooth muscle, and esophagus) and in non-Hodgkin lymphomas |
| 03/17/2009 | US7504512 BCL-X1 protein inhibitors; anticarcinogenic agents |
| 03/17/2009 | US7504511 e.g. N-[4-(5-Butyl-2-methoxyphenyl)-1,3-thiazol-2-yl]-4((4-[2-(S)-(hydroxymethyl)pyrrolidin-1-yl]piperidin-1-yl)carbonyl)benzamide; antiinflammatory, anticarcinogenic, antidiabetic, analgesic agent |
| 03/17/2009 | US7504508 PGD2 receptor antagonists for the treatment of inflammatory diseases |
| 03/17/2009 | US7504507 carboxamide linked compounds based on benzo[b][1,6]naphthyridin-1 (2H)-one, which differ from previous acridine based compounds by the incorporation of a lactam or thiolactam function in one of the outer rings |
| 03/17/2009 | US7504506 Therapeutic compounds and uses thereof |
| 03/17/2009 | US7504504 Methods of preparing aripiprazole crystalline forms |
| 03/17/2009 | US7504501 Antiprotozoal imidazopyridine compounds |
| 03/17/2009 | US7504500 Method for the production of pyrrolidine-1,2-dicarboxylic acid-1-(phenyl(-amide))-2(phenyl(-amide)) derivatives and 1-(phenylcarbamoyl)-pyrrolidine-2-carboxylic acid derivatives as intermediate products |
| 03/17/2009 | US7504497 Thrombosis; anticoagulants; renal dialysis; bioavailability |
| 03/17/2009 | US7504483 α-β C4BP-type recombinant heteromultimeric proteins |
| 03/17/2009 | US7504437 Acetylcholinesterase inhibitor; Alzheimer's diseases, Hubtington disease, antidepressants |
| 03/17/2009 | US7504436 Bioisosteres of actinonin |
| 03/17/2009 | US7504435 Method for stimulating weight loss and/or for lowering triglycerides in patients |
| 03/17/2009 | US7504434 3-(acetylamino)-4-{[amino(imino)methyl]amino}-6-carboxy-3,4-dihydro-2H-pyran-2-yl)-dimer; viricide; influenza A or B infection, parainfluenza, mumps or Newcastle disease, myxovirus infections; stability; long time in lungs |
| 03/17/2009 | US7504433 e.g. (2-Methyl-4-{2-[3-methyl-5-(4-trifluoromethyl-phenyl)-thiophen-2-yl]-propylsulfanyl}-phenoxy)-acetic acid;peroximose proliferator activated receptor; antidiabetic agent,atherosclerosis |
| 03/17/2009 | US7504431 Sulfonyl amide inhibitors of calcium channel function |
| 03/17/2009 | US7504430 Maleiimide anti-tumor phosphatase inhibitors |
| 03/17/2009 | US7504429 Receptor or non-receptor types; 1H-pyrrole-3-carboxylates; anticarcinogenic, antidiabetic, antiproliferative agents; autoimmune and Crohn's diseases, acromegaly, aging resistance; coadminister tamoxifen, raloxifene, taxol, trastuzumab, tirofiban or a COX-2 inhibitor |
| 03/17/2009 | US7504428 anxiety, depression, epilepsy, schizophrenia, and cognitive disorders; gamma -Aminobutyric acid receptors modulators; 5,7-Di-tert-butyl-3-hydroxy-3-trifluoromethyl-1,3-dihydro-indol-2-one |
| 03/17/2009 | US7504427 Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses |
| 03/17/2009 | US7504426 Antiallergens; rhitinis; antiinflammatory agents |
| 03/17/2009 | US7504425 Compounds useful in the treatment of anthrax and inhibiting lethal factor |
| 03/17/2009 | US7504424 novel hydantoin derivatives to inhibit matrix metalloproteinases (MMPs), a disintegrin and metalloproteases (ADAMs) and/or tumor necrosis factor alpha converting enzyme (TACE) and in so doing prevent the release of tumor necrosis factor alpha (TNF- alpha ); autoimmune diseases; side effect reduction |
| 03/17/2009 | US7504423 e.g. 3-((S)-2-amino-2-{trans-4-[4-(5-cyano-2-pyridinyl)-1-piperazinyl]-1-cyclohexyl}acetyl)-1,3-thiazolidine; dipeptidyl-peptidases inhibitor; suppress cleavage of glucagon-like peptides (GLP-1) by inhibition of DPP-IV; antidiabetic agent; obesity, non insulin-dependent diabetes |
| 03/17/2009 | US7504422 Polyamine compounds |
| 03/17/2009 | US7504421 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use |
| 03/17/2009 | US7504420 Compounds which inhibit beta-secretase activity and methods of use |
| 03/17/2009 | US7504419 Diastereomers of 4-aryloxy-3-hydroxypiperidines |
| 03/17/2009 | US7504417 Substituted benzene derivatives or salts thereof |
| 03/17/2009 | US7504416 4-substituted quinolines as antitumor agents |
| 03/17/2009 | US7504415 Therapeutic agent for glomerular disease |
| 03/17/2009 | US7504414 Useful as adjuvants to chemotherapy or radiation therapy to treat cancer; as inhibitors of checkpoint kinase Cds1 (in man also known as Chk2); 2-[4-(3,4-dichloro-phenoxy)-phenyl]-1H-imidazo[4,5-b]pyridine-5-carboxylic acid amide |
| 03/17/2009 | US7504413 N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases |
| 03/17/2009 | US7504412 Melanin concentrating hormone receptor antagonists; such as n-(2-cyclopropyl-3-methylimidazo[1,2-a]-pyridin-6-yl)-4-(2-pyridyl)benzamide; central nervous system, cardiovascular and metabolic disorders; synthesis |
| 03/17/2009 | US7504411 2,3,6-Trisubstituted-4-pyrimidone derivatives |
| 03/17/2009 | US7504410 such as N-[3-[[5-bromo-4-[[3-[[[1-(trifluoromethyl)cyclobutyl]carbonyl]amino]propyl]amino]-2-pyrimidinyl]amino]phenyl]-1-pyrrolidinecarboxamide; Chks (checkpoint kinases), Akts (protein kinases B) and Pdks (phosphoinositide-dependent kinases) inhibitors; antiproliferative agents |
| 03/17/2009 | US7504409 Chronic obstructive pulmonary disease; asthma; respiratory system disorders; administering 2-aminonicotinic acid, anthranilic acid, bendroflumethiazide |
| 03/17/2009 | US7504408 Quinzoline derivatives for use in the treatment of cancer |
| 03/17/2009 | US7504407 2-substituted-4-(imidazolyl or pyrazolyl alkyl)amino-6-phenyl-pyrrolo[2,3-D]pyrimidines; Adenosine receptor inhibitors; asthma, bronchodilators, vision defects, antiischemic and antiinflammatory agents |
| 03/17/2009 | US7504406 Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same |
| 03/17/2009 | US7504405 Mitotic kinesin inhibitors |
| 03/17/2009 | US7504404 Compounds as metabotropic glutamate receptor antagonists |
| 03/17/2009 | US7504403 Substituted heterocyclic compounds and methods of use |
| 03/17/2009 | US7504402 bicyclo[2.2.2]-oct-1-yl-1,2,4-triazoles; type 2 diabetes, lipid disorders, obesity, atherosclerosis, metabolic syndrome, hyperglycemia, insulin resistance; increase insulin sensitivity in muscle, liver and adipose tissue by correction of the elevated plasma levels of glucose without causing hypoglycemia |
| 03/17/2009 | US7504401 Anti-cancer agents and uses thereof |
| 03/17/2009 | US7504400 MTP inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles |
| 03/17/2009 | US7504399 Piperazine enamines as antiviral agents |
| 03/17/2009 | US7504398 potent and selective antagonists of adenosine receptors; Parkinson's disease, asthma, allergies, inflammation, atherosclerosis, hypertension, gastrointestinal disorders, cell proliferation and autoimmune diseases; sulfonamidation |
| 03/17/2009 | US7504397 mTOR inhibitor compounds |
| 03/17/2009 | US7504396 Substituted heterocyclic compounds and methods of use |
| 03/17/2009 | US7504395 Treatment for attention-deficit hyperactivity disorder |
| 03/17/2009 | US7504394 Bazedoxifene ascorbate |
| 03/17/2009 | US7504393 Benzylamine analogues |
| 03/17/2009 | US7504392 2,3,4,5-tetrahydro-1H-3-benzazepines and their medical use |
| 03/17/2009 | US7504391 Analogues of N-methyl, hydroxy(alkoxy)-partially saturated indeno(1,2-a)-3-benzoazeines, naphtho(1,2-a)-3-benzoazepines, and 1-phenyl-3-benzazepenes; metabolic disorders/eating disorders, e.g., obesity (dietetics), hyperphagia; antidiabetic agents; obsessive compulsive, somatoform dissociative disorders |